Reportlinker Adds US Stem Cells Research Industry

Mar 21, 2011, 12:45 ET from Reportlinker

NEW YORK, March 21, 2011 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

US Stem Cells Research Industry

This report analyzes the US Market for Stem Cells Research in US$ Million. Annual forecasts are provided for the period 2006 through 2015. The report profiles 92 companies including many key and niche players such as Advanced Cell Technology, Inc., Athersys, Inc., BioE, Inc., Cryo-Cell International, Inc., Cytori Therapeutics, Inc., Edstrom Biosciences, Inc., Geron Corporation, International Stem Cell Corporation, Neuralstem, Inc., NeuroGeneration, Inc., Osiris Therapeutics, StemCells, Inc., ThermoGenesis Corp., and ViaCord, LLC. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.


Study Reliability and Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 3

Quantitative Techniques & Analytics 3

Product Definitions and Scope of Study 3

Types of Stem Cells 3

Embryonic Stem Cells 3

Adult Stem Cells 3


Overview 4

Major Achievements Thus Far 4

Stem Cell Therapy Gaining Acceptance 4

New Growth Areas 5

Orthopedic Products - A potential growth sector 5

Utilitarian Functions of Cord Blood Stem Cells 5

Umbilical Cord Stem Cells in the Treatment of Hepatic Diseases 5

Human Umbilical Cord Blood-Derived Stem Cells to Synthesize

Insulin 5

Challenges 5

Stem Cell Research And the Ethical Angle 6


North America Dominates Global Stem Cells Market 7

Stem Cells Breakthrough Reshaping the Area of Medicine 7

New Technologies Draw Significant Attention 7

Ethical Issues and Nascent Stage - Key Market Restraints for

Stem Cells 8

Medical Tourism Picks Up in Stem Cell Therapy 8

Government Regulations Fail to Prevent Medical Tourism in

Stem Cell Therapy 9

US and Japan Surge Ahead of Europe in Stem Cell Patents 9

Table 1: Global Stem Cells Patent Analysis By Market (2008):

Percentage Breakdown of Number of Patents Issued for US,

Japan and Europe (includes corresponding Graph/Chart) 10

Table 2: Global Stem Cells Patent Analysis By Product (2008):

Percentage Breakdown of Number of Patents Issued for Adult

Stem Cells, Human Embryonic Stem Cells, Mesenchymal Stem

Cells, Hematopoietic Stem Cells, Neuronal Stem Cells and

Others (includes corresponding Graph/Chart) 10

Table 3: Leading Stem Cell Companies by Patents (2008):

Percentage Breakdown of Number of Patents Secured for Geron

Corp., Osiris Therapeutics, Olympus Corporation, Wisconsin

Alumni Research Foundation, Kourion Therapeutics AG, Japan

Science & Tech Agency and Others (includes corresponding

Graph/Chart) 10


Adult Stem Cells Hold Tremendous Potential 11

A Low Risk Investment 11

Adult Stem Cells Garner More Investments for Research 12

Low Versatility - A Major Limiting Factor for Adult Stem Cells 12

Hematopoietic Stem Cells - Enjoying Enduring Success 12

The Restraining Factors 12

Mesenchymal Stem Cells - A Promising Therapeutic Option 13

Difficulty in Isolation and Lower Understanding Hampers Growth 13

Induced Pluripotent Stem Cells - An Alternative to ESCs 13

A Peek Into the Discovery of iPS 13

Drug Development - A Major Application for iPS 14

Regenerative Medicine 14

Establishing iPS Cell Banks 15

Intractable and Congenital Disease Treatments 15

Repairing Organs 15

Embryonic Stem Cells to Transfigure the Field of Medicine 15

Lack of Safety and Efficacy Data Remains A Concern 16


Stem Cells in Disease Management 17

Stem Cell Therapy in Regenerative Medicine 17

Stem Cell Therapy - A Promising Treatment for Neurological

Disorders 18

Large-Scale Studies Imperative to Substantiate Early Positive

Results In Cardiovascular Diseases 18

Stem Cell Therapy in Cancer 18

Stem Cells Set Foot in Personal Care 19

Aging Population to Drive Orthopedic Stem Cell Market 19

Other Diseases 20

Stem Cells in Drug Discovery 20

Tools for Drug Development 21


Laws Governing Stem Cells Research - The Divided World 22

Laws and Regulations in Stem Cells Research in Select Countries 22


Stem Cell Research 23

Stem Cells - Description 23

Types of Stem Cells 23

Embryonic Stem Cells 23

mES and hES 23

R-NSCs 24

Adult Stem Cells 24

Hematopoietic Stem Cells 25

Mesenchymal Stem Cells 25

Umbilical Cord Stem Cells 25

Neuronal Stem Cells 25

Dental Stem Cells 25

Pluripotent Adult Stem Cells 26

Other Key Cell Types 26

The Stem Cell Line - Cell Division 26

Stem Cells - Properties 27

Ability to Renew on its Own 27

Potency 27

Definitions of Various Potencies 27

Identification of Stem Cells 27

Stem Cells - Applications 28

History of Stem Cells 28

Stem Cells - Services and Products 29

Significance of Stem Cell Products/Services 29


Parthenogenetic Stem Cells Holds Potential in the Treatment of

Thalassemia 30

hESCs - A Potential Source for Unlimited Supply of Functional

Platelets 30

Sperm-Producing Stem Cells For Diabetes Treatment -

Researchers Explore Prospects 31

Cellonis Achieves Outstanding Results of Its Stem Cell Therapy

for Diabetes 31

Stem Cells From Fallopian Tubes - A Prospective New Source 31

Stem Cells from Fat - Enhancing Stem Cells Accessibility 32

Skin Cells to Stem Cells - A New Promising Method 32

Stem Cells to Repair Brain Damage After A Stroke 33

ACT Shows hESCs' Potential to Become An Unlimited Source for

Functional RBCs 33


StemCells Launches New Antibody Reagents 35

Arteriocyte Introduces Nanex Hematopoietic Stem Cell Expansion

Kit 35

Vitrolife Unveils Growth Factors and Cytokines for Stem Cell

Cultivation 36

BioTime to Introduce New Product Line of Stem Cell Products 36

Chemaphor Introduces Stem Cell Regenerative Therapy 36

Stempeutics Research Malaysia to Launch Ischemic CS Therapy 36

Vitro Diagnostics Launches Novel Serum-free Stem Cell Growth

Medium 36

ThermoGenesis to Launch Res-Q System 37

Invitrogen to Introduce New Technology for Safe Stem Cell

Treatment 37

Millipore Unveils MilliTrace™ Stem Cell Lines 38

Millipore Unveils ESGRO Complete™ PLUS medium 38

Bayer Launches Reformulated Liquid Leukine® 38

Shenzhen Beike Biotechnology and CMC Launch NBPD's SCRM

Industrial Project 38

Vitro Unveils New Products Supporting Stem Cell Research 39

Endogenous Stem Cells Activators Introduces KRONOS IV 39

ArunA Biomedical and Open Biosystems Launch iPS Kit 40

Invitrogen Introduces Neon Transfection Device 40

Invitrogen Introduces Xenogeneic-Free Media 40

NanoInk Unveils NanoStem Cell Division 40

Advanced Cell Technology Unveils New Process for Functional

Hepatocytes Generation 41


NeoStem Merges with Progenitor Cell Therapy 42

EHS Enters into Joint Venture with Celulas Genetica 42

RJ to Form New Subsidiary 42

NuPotential and VistaGen Receive NIH Grant for Development of

iPS Cells (US) 42

BioCells Argentina Launches Dental Pulp Stem Cells Storage

Program 43

EHSI Forges Option Deal with OceanBASIS 43

EHSI and Regenetech Ink License Agreement 44

Transposagen Biopharmaceuticals and CDI Ink Non-exclusive

License Agreement 44

Kiadis Signs Licensing Agreement with Hospira to Develop and

Market Hematology Product 44

ACT Obtains FDA Approval for Human Clinical Trials of hESCs

for Dry AMD 44

OncoMed Commences Phase I Clinical Trial of OMP-59R5 45

Advanced Cell Technology and Roslin Cells Ink MoU 45

Mesoblast Takes Over Angioblast 46

Power3 Medical Products and Rozetta-Cell Life Sciences to Merge 46

University of California and BioTime Ink Material Transfer

Agreement 46

ISCO And John Mauldin Commence Marketing Alliance for Skincare

Products 47

Cord Blood America Inks Letter of Intent to Take Over Cryo-

Cell Mexico 47

Mesoblast Enters into Stem Cell Marketing Deal with US Company 47

Bayer HealthCare Enters into Alliance with OncoMed

Pharmaceuticals 47

SiriCell Technologies Acquires Remaining Stake in

International Stem Cell JV 48

StemCells Receives Swissmedic Approval for Neural Stem Cells

Trial In Chronic Spinal Cord Injury 48

ACT Obtains FDA Clearance for Human Clinical Trials of hESCs

for SMD 48

ReNeuron Treats First Patient in Stem Cell Therapy Clinical

Trial for Stroke 49

Amedica/US Spine Inks a Licensing and Distribution Agreement

with BioDlogics 49

Vet-Stem Inks Sub-Licence Agreement with Australian Veterinary

Stem Cells 50

Athersys Obtains FDA Approval for Phase II Trial for IBD Using

MultiStem® 50

Stemedica and AnC Form Stem Cells JV 50

Fate Therapeutics Enters into Collaboration and Licensing

Agreement with BD 50

BrainStorm Obtains Clearance for Stem Cell Therapy Clinical

Trial for ALS in Israel 51

Shrink Nanotechnologies Enters Final Stage of StemDisc

Commercialization 51

Cryo-Cell's License Partner S-Evans Biosciences Opens New

Laboratory 51

Geron Receives FDA Approval to Initiate Clinical Trials of

hESCs for Treating Acute Spinal Cord Injuries 51

Cytori Therapeutics' Celution System Obtains European Approval 52

TGA Grants Approval to Mesoblast to Supply MPC Products 52

BioTime Inks Partnership with Hadasit Bio to Take over ES Cell

International 52

AssureImmune and Banco Merge 53

Salk Institute to Use Cyntellect's Cell Processing Workstation

LEAP™ 53

STEMCELL Inks Agreement with Stanford University for Virus

Free Technique 53

NeoStem Inks Partnership Agreement with Catholic Church 53

Stemgent Signs Deal with Miltenyi to Co-develop and Market

Stem Cell Research Products 53

BioTime Acquires ES Cell International 54

Cipla Enters into Partnership with Stempeutics to Enter Stem

Cell Segment 54

Vitro Diagnostics Signs Contract with HemoGenix 54

Fate Acquires Verio Therapeutics 55

Vitrolife Inks Licensing Agreement with Finn-Medi Research 55

AXM Pharma to Establish Stem Cell Plant 55

Stem Cell Therapy Merges with Histostem 55

Cord Blood America Enters into Contract with BioE for Cord

Blood Processing System 55

Pfizer Acquires Rights to Athersys' Stem Cell Therapy 56

Enterprise Investors Acquires Large Interest in PBKM 56

Fate Therapeutics to Distribute Stem Cell Products through

Becton Dickinson 56

NHMC Merges with BioStem Genetics 57

Riverside Acquires Crioestaminal 57

Cryo-Cell International Signs Distribution Agreement with S-

Evans Biosciences 57

Jordanian Stem Cell Purchases Stemedica International's Stem

Cell Technology 57

BrainStorm Enters into Agreement with Protein Production Services 58

Novartis Acquires Opexa's Stem Cell Technology 58

ThermoGenesis Expands Alliance with Celling Technologies 58

Bioheart to Test MyoCell SDF-1 in REGEN Trial 59

Osiris Initiates Enrolment for Prochymal Phase II Clinical

Trial for Type I Diabetes Treatment 59

Stirling Divests Interest in Australian Stem Cell Healthcare 60

iZumi Bio Merges with Pierian 60

iZumi Collaborates with CiRA to Expand iPSC Technology 60

Novartis Forges Research and Development Partnership Agreement

with Epistem 61

Healthcare of Today Acquires Regenetech 61

Neuralstem and China Medical University to Co-develop

Treatment for Stem Cell Stroke 62

Cytori Inks Agreement with GE Healthcare for StemSource®

Technology Commercialization 62

MedCell Bioscience Merges with NovaThera 63

StemCells Acquires Stem Cell Sciences 63

BioSante Pharmaceuticals Merges with Cell Genesys 63

Cell Therapeutics Enters into Joint Venture with Spectrum

Pharmaceuticals 64

Cryo-Cell International Enters into Collaboration with

Cryopraxis Cryobiology 64

Embryome Sciences Signs Partnership Agreement with

Reproductive Genetics Institute 65

ENKAM Inks Licensing Agreement with STEMCELL 65

Sigma-Aldrich Inks Distribution Agreement with AlphaGenix 66

ThermoGenesis and Celling Technologies Extend Collaboration 66

Vivalis Enters into Collaboration with SAFC Biosciences 66

ReNeuron Enters into Agreement with Angel Biotechnology Holdings 67

Cellartis Signs Agreement with ReproCELL 67

Cellartis and AstraZeneca Extend Collaboration 68

Embryome Sciences and Millipore Sign Co-Marketing Agreement 68

Cytori Enters into Partnership with GE Healthcare 68

Stemgent Enters into Co-Exclusive Marketing Agreement with

CellDesign 69

MultiCell Technologies and Maxim Biotech Sign R&D Agreement 70

GE Healthcare Collaborates with Geron Corporation 70

Moraga Biotechnology Licenses BLSCs to Pharmacells 71

CordLife Develops Stem Cell Therapies in India 71

NsGene Receives European Patent Rights 72

Pfizer to Invest in Stem Cell Research 72

SCTI Commences Histostem Products Distribution Process 72

Geron Secures FDA Approval for Human Trial of Embryonic Stem

Cell-Based Therapy 73

BioE Obtains FDA Marketing Approval for PrepaCyte-CB 73

StemCells Obtains FDA Approval for Phase I Clinical Trial of

HuCNS-SC® Cells in Treatment of PMD 73

Athersys Obtains IND for Using Multistem in Treating Ischemic

Stroke 74

Athersys Presents Initial Dosing Data of MultiStem® Phase I

Trial in AMI 74

ACT Creates Five Lines of hESCs Without Embryo Destruction 74

BioE Inks Agreement with StemSoft 75

ACT's Technology Generates 140 Cell Types from hESC 75

ACT Develops Process for Generating Functional Hepatocytes

from hESCs 76

Applied Biosystems Merges with Invitrogen 76

Bennett, Coleman and Co Acquires Stake in Stem One Biologicals 76

BMXP Holdings Acquires Freedom Environmental Services 76

Saints Capital Completes Neuronyx Acquisition 77

Intercity Acquires Exordia 77

iPS and Stem Cell Merge with CDI Merge 77

Biohellenika Acquires Exclusive Rights of Cytori's StemSource

Cell Bank 78

International Stem Cell Signs Agreement with Millipore

Corporation 78

ReNeuron Enters into Agreement with Angel Biotechnology 78

ThermoGenesis and Celling Technologies Ink a Distribution

Agreement 79

BioTime and Embryome Ink a Deal with International Stem Cell 79

Cryo-Cell Enters into Agreement with Saneron 80

Genzyme Enters into Alliance with Osiris 80

VivoMedica Enters into Collaboration with Cellartis 81

Histostem Signs MOU with Stem Cell Therapy 81

Vantus Inks Agreement with US Davis Center for Equine Health 81

Stem Cell Sciences Enters into Agreement with Pfizer 82

Sigma-Aldrich Inks Distribution Agreement with AlphaGenix 82

Cellartis Signs Agreement with Pfizer 83

Ortec Changes Corporate Name to Forticell Bioscience 83

FDA Grants Approval to Genzyme's Mozobil 83

Pfizer Inaugurates Pfizer Regenerative Medicine Research Facility 84

Stem Cell Therapeutics Receives Australian Patent 84

STEMCELL Technologies Secures License Rights to Geron IP 84

BioTime Starts Embryonic Stem Cell Solution Facility 85

Geron Successfully Transplants Pancreatic Islet-Like Clusters 86

StemCells Secures US Patent 86

PerkinElmer Takes Over ViaCell 86

Athersys' MultiStem® Receives US FDA Nod for Phase I Trial in

BMT Support and AMI 87

BioE Teams Up with Phillips Plastics for Stem Cell Therapeutics 87


Advanced Cell Technology, Inc. (US) 88

Athersys, Inc. (US) 88

BioE, Inc. (US) 89

Cellartis AB (Sweden) 89

Cryo-Cell International, Inc. (US) 89

Cytori Therapeutics, Inc. (US) 90

ES Cell International (Singapore) 90

Gamida Cell Ltd. (Israel) 91

Genzyme Corporation (US) 91

Geron Corporation (US) 91

International Stem Cell Corporation (US) 92

Mesoblast Ltd. (Australia) 92

Neuralstem, Inc. (US) 93

NeuroGeneration, Inc. (US) 93

Osiris Therapeutics, Inc. (US) 94

StemCells, Inc. (US) 94

ThermoGenesis Corp. (US) 95

ViaCord, LLC (US) 95


Table 4: Global Recent Past, Current & Future Analysis of

Adult Stem Cell Research By Geographic Region - US, Europe and

Rest of World Markets Independently Analyzed with Annual

Investment Figures in US$ Million for Years 2006 through 2015

(includes corresponding Graph/Chart) 96

Table 5: World 10-Year Perspective for Adult Stem Cell

Research by Geographic Region - Percentage Breakdown of Annual

Investments for US, Europe and Rest of World Markets for Years

2006, 2010 & 2015 (includes corresponding Graph/Chart) 97


A.Market Analysis 98

North America - Spearheading Global Stem Cells Market 98

US - The Market Leader for Stem Cell Research Worldwide 98

Interest in Adult Stem Cell Research Continues 99

Cosmetic Enhancements Ahead of Therapies for Diseases 99

Embryonic Stem Cell Research in the US Held Back by Lack of

Federal Funding 100

Vacillating US Policy on Federal Funding for hESC Research 100

US Revokes Ban On Federal Funding for hESC Research 100

Federal Funding Remains the Key for Further Progress in the

Sector 101

US Court's Decree to Block Federal Funding for hESC Research

to Affect Biotech Industry 101

Competitive Scenario 102

Table 6: Leading Players in the US Stem Cell Therapeutics

Market (2007): Percentage Breakdown of Value Sales for

ViaCell Inc., Cryo-Cell, Osiris Therapeutics Inc.,

International Stem Cell Corporation, Geron Corp., Cytori

Therapeutics Inc., Athersys Inc., and Others (includes

corresponding Graph/Chart) 102

B.Market Analytics 103

Table 7: US Recent Past, Current & Future Analysis of Adult

Stem Cell Research Market Analyzed with Annual Investment

Figures in US$ Million for Years 2006 through 2015 (includes

corresponding Graph/Chart) 103

14. EUROPE 104

A.Market Analysis 104

The UK Policy on hESC Remains In Favor of Developing the

Science 104

UK Adopts Practical Approach In Addressing Moral Issues 104

UK- The First Country to Allow Therapeutic Cloning 104

B.Market Analytics 105

Table 8: European Recent Past, Current & Future Analysis of

Adult Stem Cell Research Market Analyzed with Annual

Investment Figures in US$ Million for Years 2006 through

2015 (includes corresponding Graph/Chart) 105


A.Market Analysis 106

The Rise of Asia in Stem Cells Research 106

US Ban on Federal Funds for hESC Research Boosts Asian Presence 106

Emergence of China in the Global Stem Cell Research Space 106

The Indian Stem Cell Research Market - An Overview 107

B.Market Analytics 108

Table 9: Rest of World Recent Past, Current & Future

Analysis of Adult Stem Cell Research Market Analyzed with

Annual Investment Figures in US$ Million for Years 2006

through 2015 (includes corresponding Graph/Chart) 108


Total Companies Profiled: 90 (including Divisions/Subsidiaries - 97)


Region/Country Players


The United States 67

Canada 3

Japan 1

Europe 14

France 1

The United Kingdom 7

Spain 1

Rest of Europe 5

Asia-Pacific (Excluding Japan) 9

Latin America 1

Middle-East 2


To order this report:

: US Stem Cells Research Industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg



US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker